Table 5.

Burdens, harms, benefits, and efficiencies for fecal immunological technique and fecal occult blood testing at 3-year adherence rates compared to recommended intervals for colonoscopy and mt-sDNA, ages 50-75, per 1000 people screened

		Burdens and harms			Benefits
CISNET model	Test	Stool tests	Total COL	Complications	LYG	CRC DA	CRC incidence reduction	CRC mortality reduction	% of COL 10y LYG	COL per LYG	Complications per LYG	Complications per DA
SimCRC	COL 10y	0	4007	14	275	24	81%	87%	100%	15	0.051	0.58
	FIT3y	6887	971	6	212	18	45%	65%	77%	5	0.028	0.33
	hsFOBT3y	6456	1286	7	212	18	47%	66%	77%	6	0.033	0.39
	mt-sDNA3y	5990	1701	9	250	22	63%	78%	91%	7	0.036	0.41
MISCAN	COL 10y	0	4101	15	248	22	62%	79%	100%	17	0.060	0.68
	FIT3y	6795	995	7	176	15	28%	55%	71%	6	0.040	0.47
	hsFOBT3y	6302	1296	8	175	15	30%	55%	71%	7	0.046	0.53
	mt-sDNA3y	5779	1714	9	215	19	43%	68%	87%	8	0.042	0.49
CRC-SPIN	COL 10y	0	4049	15	270	24	88%	90%	100%	15	0.056	0.62
	FIT3y	6857	1081	7	178	16	49%	59%	66%	6	0.039	0.44
	hsFOBT3y	6498	1317	8	183	16	53%	61%	68%	7	0.044	0.50
	mt-sDNA3y	5927	1827	10	226	20	68%	76%	84%	8	0.044	0.50

CISNET: National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network; COL: Colonoscopies; COL 10y: Colonoscopy at a 10-year interval; LYG: Life-years gained; CRC: Colorectal cancer; MISCAN: Microsimulation screening analysis; CRC-SPIN: Colorectal cancer simulated population model for incidence and natural history; SimCRC: Simulation model of colorectal cancer; DA: Deaths averted; FIT: Fecal immunological test.